Hyperparathyroidism jaw tumour syndrome is a rare autosomal dominant inherited endocrine neoplasia syndrome, which predisposes carriers to develop a triad of multiple ossifying fibromas of the maxilla and mandible, parathyroid adenomas and carcinomas (with consequent hyperparathyroidism) as well as renal and uterine tumours. The prevalence of this condition is unknown. Patients typically present initially with symptoms and signs of a jaw tumour. A high index of suspicion is required for the underlying diagnosis to be recognised, enabling appropriate management of jaw lesions, treatment of hyperparathyroidism, if present, as well as early detection of malignant disease and screening of family members.

Teaching points
- HPT-JT is a rare autosomal dominant inherited endocrine neoplasia syndrome.
- HPT-JT causes facial disfigurement, morbidity secondary to hyperparathyroidism and malignancy.

Introduction

Hyperparathyroidism jaw tumour syndrome (HPT-JT) is a rare autosomal dominant inherited endocrine neoplasia syndrome, which predisposes carriers to develop a triad of multiple ossifying fibromas of the maxilla and mandible, parathyroid adenomas and carcinomas (with consequent hyperparathyroidism), as well as renal and uterine tumours.

Genetics

HPT-JT is inherited in an autosomal dominant pattern and can demonstrate incomplete penetrance. Instances of sporadic mutations arising de novo have been recorded [1]. The syndrome arises from a gene mutation, which inhibits the production of normal parafibromin, a protein that regulates cell proliferation and can arrest the cell cycle [1]. The gene responsible for parafibromin expression is the HRPT2 tumour suppressor gene (also known as the CDC73 gene), which has been localised to a 34-cM region on 1q25 - q31 [2]. Mutations of HRPT2 are identified in most individuals affected by HPT-JT (and many of their asymptomatic family members) [3]. Loss of normal parafibromin expression allows certain tissues to propagate unimpeded. Gene sequencing is of use in confirming the diagnosis and differentiating the disease from...
other inherited endocrine neoplasia syndromes which also have parathyroid manifestations (e.g., multiple endocrine neoplasia (MEN) types I and II).

Clinical presentation

Individuals with HPT-JT typically present with jaw and teeth deformities secondary to ossifying fibromas of the maxilla and mandible. These produce a hard, deforming jaw swelling, which can cause early tooth displacement. Alternatively, they may present with symptoms and signs of hypercalcaemia secondary to hyperparathyroidism due to an underlying parathyroid adenoma or carcinoma. A few patients will also be detected incidentally with a high serum calcium on blood biochemistry that subsequently prompts further investigation. Unfortunately, some patients can also present with the sequelae of renal, uterine or parathyroid malignancy.

Imaging findings

i. Ossifying fibromas

Ossifying fibromas of the jaw are a type of benign fibro-osseous lesion detected in approximately 50% of HPT-JT individuals and present in adolescents or young adults [2]. In contrast, sporadic ossifying fibromas of the jaw are rare and typically occur in an older age group [4]. Ossifying fibromas of the jaw arise from the mesenchymal cells of the periodontal ligament, the fibrous connective tissue found within the periodontal space, which secures the tooth [5]. They are composed of fibrous tissue with varying amounts of mature bone, osteoid and cementum [6].

On plain film and CT ossifying fibromas appear as well-circumscribed expansile lesions arising within the mandible or maxilla (Fig. 1). They are commonly unilocular, but can be multilocular and demonstrate sizeable growth (greater than 10 cm) [5]. On plain film imaging, they are usually lucent, but can demonstrate a mixed opacity or be completely radiopaque, depending on the relative fibrous and calcified components [7]. They typically have a sclerotic rim. On CT they demonstrate internal soft tissue density, which reflects the fibrous component (Fig. 2). On MR T1-weighted imaging they return low to intermediate signal, the low signal areas reflecting the osseous component. On T2-weighted imaging, they contain a mixture of low and high signal components reflecting the osseous and fibrous components, respectively [6]. The fibrous component of the tumour enhances following administration of contrast [6]. Ossifying fibromas typically do not cause root absorption, which is a feature of more aggressive lesions such as ameloblastomas, and unlike radicular or dentigerous cysts, there is no association with unerupted teeth [4].
Ossifying fibromas of the jaw are benign lesions with the risk of malignant degeneration being less than <0.5 % [5]. However, they demonstrate locally invasive features, e.g., they may splay the teeth [4]. They are expansile and can cause facial asymmetry. They can extend into the maxillary sinus (Fig. 3). Extension into the orbital floor may precipitate periorbital swelling, orbital pain or changes in visual acuity (Fig. 4). If left untreated, ossifying fibromas may continue to enlarge and become severely disfiguring (Fig. 5).

The distinction from fibrous dysplasia and osteolytic Brown tumours of hyperparathyroidism is an important one as both conditions may also arise in the jaw. Fibrous dysplasia produces ill-defined bony expansion and has a characteristic ‘ground glass’ appearance, but it can be indistinguishable from an ossifying fibroma on imaging (Fig. 6) underlining the importance of multidisciplinary team discussion in making the diagnosis of an ossifying fibroma, and the need to review and correlate clinical, imaging and histopathological evidence [4]. As with ossifying fibromas of HPT-JT, Brown tumours may also appear on imaging as lucent jaw lesions with evidence of hyperparathyroid bone disease in the surrounding bone [7]. However, Brown tumours are purely lytic lesions, which lack the sclerotic rim associated with ossifying fibromas. Other important differentials are cementomas, which appear uniformly dense when mature, and osteosarcomas, which appear as ill-defined destructive lesions characterized by aggressive periosteal reaction [6].

Parathyroid adenomas and carcinomas

HPT-JT patients with parathyroid adenomas or carcinomas will develop primary hyperparathyroidism and consequent hypercalcaemia. Patients may present with typical but non-specific symptoms of hypercalcaemia including malaise, depression, renal stones and abdominal pain or incidentally identified following identification of a raised serum calcium on blood biochemistry. Hyperparathyroid bone disease is characterised by subperiosteal bone resorption, sclerotic bone changes and/or terminal tuft reabsorption (Fig. 7) [8].
presence of jaw lesions in combination with bone changes suggestive of hyperparathyroid bone disease should prompt the radiologist to consider HPT-JT and review for a parathyroid lesion (Fig. 8).

In HPT-JT, parathyroid adenomas develop in a younger population with a mean age of diagnosis at 33 years, and there is a propensity for them to reoccur following removal as well as developing new adenomas [2]. In contrast, sporadic parathyroid adenomas typically occur as solitary single episode tumours beyond 40 years of age, with a predilection for the female population [9]. HPT-JT individuals are at a higher risk of developing parathyroid carcinoma, a rare malignancy in the general population [10].

Parathyroid adenomas and carcinomas appear as solitary solid soft tissue masses the majority of which are juxtathyroid and located immediately posterior or inferior to the thyroid gland, although they can be located as inferior as the mediastinum [11]. First line assessment to identify parathyroid gland enlargement varies between institutions, but is typically performed with a combination of ultrasound and nuclear medicine scintigraphy. On ultrasound, parathyroid adenomas and carcinomas are uniformly hypoechoic and often demonstrate increased vascularity with identification of a vascular pedicle (Fig. 9) [11]. Nuclear medicine
**Fig. 7**  
(a) Axial CT bone reformat through skull base  
(b) coronal CT bone reformat of left mandible in a 50-year-old male with HPT-JT and extensive hyperparathyroid bone disease. There is a ‘salt and pepper’ appearance to the skull base secondary to trabecular bone reabsorption. Subperiosteal bone reabsorption of the lamina dura gives a floating appearance to a left lower molar tooth (b). There has been substantial maxillary bone loss and loss of the upper left dentition.

**Fig. 8**  
(a) Sagittal oblique CT and  
(b) axial CT image of the skull base  
(c) axial CT upper thorax.  
34-yr-old female with undiagnosed HPT-JT who underwent a CT to assess a left mandibular ramus lesion (a) subsequently proven to be an ossifying fibroma. She was incidentally noted to have generalised bony sclerosis (b) suggestive of hyperparathyroid bone disease and further imaging (c) revealed a retrosternal parathyroid adenoma (arrowhead) anterior to the left brachiocephalic vein.

**Fig. 9**  
(a) Longitudinal ultrasound image of a parathyroid adenoma in a 54-yr-old female with HPT-JT. The adenoma (arrowhead) corresponds to the elongated hypoechoic structure caudal to the thyroid. On application of colour Doppler (b) the lesion is demonstrated to be hypervascular.
Fig. 10  A nuclear medicine parathyroid scintigraphy study (image courtesy of Dr Cindy Leung, Barts and The London). The Technetium pertechnetate ($^{99m}$Tc-pertechnetate) image (upper row, far left) demonstrates localization of the thyroid gland. $^{99m}$Tc-Sestamibi (MIBI) images show a focal area of significant increased tracer uptake inferior to the left thyroid lobe, which persists on early (centre and far right, upper row) and delayed imaging (centre and far right, lower row). Imaging characteristics are consistent with a parathyroid adenoma. Tracer uptake elsewhere is physiological.

Fig. 11  a) Transverse ultrasound image of thyroid and b) coronal FDG PET-CT of the thorax of a 50-year-old male with HPT-JT who has a parathyroid carcinoma and a bone metastasis at presentation. The ultrasound (a) demonstrates a hypoechoic parathyroid neoplasm (arrowhead) indenting the thyroid with findings suspicious for underlying invasion of the prevertebral musculature. The PET-CT demonstrates intense tracer uptake in the left posterior T8 vertebral body, which was proven on biopsy to be a metastatic deposit. Focal uptake in the left 7th rib is secondary to a rib fracture. HPT-JT patients have a greater predisposition to develop parathyroid carcinomas than the general population.
‘wash out’ scintigraphy using Technetium 99 m Sestamibi tracer is the ‘gold standard’ for the detection of parathyroid adenoma [12]. The tracer is retained within parathyroid adenoma and carcinomas and demonstrates increased uptake on both early and late imaging (Fig. 10). In contrast, there is rapid wash out of tracer from the adjacent thyroid gland [13]. CT and MRI are employed when there is non-concordance between first line imaging investigations and in patients who have typically undergone previous surgical intervention to remove a parathyroid adenoma/carcinoma [11]. Selective venous PTH sampling can be used to localize a suspected occult parathyroid adenoma.

Hyperparathyroidism and hypercalcaemia are often more profound in parathyroid carcinoma compared to parathyroid adenomas; however, the imaging appearances can be indistinguishable although parathyroid carcinomas are typically larger and may demonstrate invasive features, e.g., invasion of the prevertebral muscles and surrounding structures (Fig. 11) [14]. Therefore, in the absence of obvious metastatic disease, the diagnosis is typically confirmed following surgical resection.

iii. Renal and uterine tumours

Wilms tumours, nephroblastosomas, harmatomas, papillary renal cell carcinomas and an increased incidence of simple renal cysts have been reported in HPT-JT patients [15–17]. There is a reported higher incidence of uterine carcinomas and uterine polyposis in females with HPT-JT [17].

Management

The management of ossifying fibromas in HPT-JT comprises complete surgical excision of jaw lesions with bone grafting and reconstruction. Patients with parathyroid lesions on imaging will often undergo a subtotal parathyroidectomy or total parathyroidectomy with autotransplantation [10]. The decision to perform total parathyroidectomy is based on consideration of the hormone levels and severity of parathyroid bone disease. HPT-JT individuals should be managed with a medical surveillance plan [10]. Plain film or CT can be used to detect jaw lesions, serum calcium measurements to detect parathyroid lesions and a combination of ultrasound and MRI can be used to evaluate the kidneys and uterus. Currently, there is no standardized management plan. Finally, family members can be screened genetically for the condition.

Conclusion

HPT-JT is a rare syndrome with a significant potential for the development of facial disfigurement, morbidity secondary to hyperparathyroidism and malignancy. This topic is important for radiologists because patients will often first present with ossifying fibromas of the jaw. A high index of suspicion is required for the underlying diagnosis to be recognised, enabling treatment of hyperparathyroidism, early detection of malignant disease and screening of family members. Recurrent or multiple jaw lesions or the combination of jaw lesions and hyperparathyroid bone disease on imaging should raise the possibility of HPT-JT.

References

1. Woodward GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF (2005) Parafibromin, product of the hyperparathyroidism-jaw syndrome tumour gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24(7):1272–1276
2. Hobbs M, Pole A, Pidwirny G, Rosen I, Zarbo R, Coon H (1999) Hyperparathyroidism-jaw tumour syndrome: The HRPT2 Locus is within a 0.7 cm region on chromosome 1q. Am J Hum Genet 64: 518–525
3. Masi G, Barzon L, Jacobone M, Viel G, Porzionato A, Macchi V, De Caro R, Favia G, Palu G (2008) Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocrinol Relat Cancer 15:1115–1126
4. Zegalie N, Speight P, Martin L (2015) Ossifying fibromas of the jaws and craniofacial bones. Diagn Histopathol 21:351–358
5. Liu Y, Wang H, You M, Yang Z, Miao J, Shimizu Tani K, Kpseki T (2010) Ossifying fibromas of the jaw bone: 20 cases. Dentomaxillofacial Radiol 39:57–63
6. Hamsberger R, Glastonbury C, Michel M, Koch B. Diagnostic imaging: Head and Neck. Lippincott Williams & Wilkins publishing; 2010
7. Scholl R, Kellett H, Neumann D, Lurie A (1999) Cysts and cystic lesions of the mandible: clinical and radiologic-histopathologic review. Radiographics 19(5):1107–1124
8. McDonald D, Parman L, Speights V (2005) Primary Hyperparathyroidism due to parathyroid adenoma. Radiographics 25(3):829–834
9. Miller B, Dimick J, Wainess R, Burney R (2008) Age-and sex-related incidence of surgically treated primary hyperparathyroidism. World J Surg 32:795–799
10. Chen JD, Morrison C, Zhang C, Kahnosi K, Carpten JD, Teh BT (2003) Hyperparathyroidism-jaw tumour syndrome. J Intern Med 253:634–642
11. Johnson N, Tublin M, Ogilvie J (2007) Parathyroid imaging: Technique and role in the preoperative evaluation of primary hyperparathyroidism. Am J Roentgenol 188:1706–1715
12. Westrich R, Brandwein M, Mechanick J, Bergman D, Urken M (2003) Preoperative parathyroid localization: correlating false-negative technetium 99m sestamibi scans with parathyroid disease. Laryngoscope 113:567–572
13. Palestro C, Tomas M, Tronco G (2005) Radionuclide imaging of the parathyroid glands. Semin Nucl Med 35:266–276
14. Digonnet A, Carlier A, Willems E, Quiriny M, Dekeyser C, de Saint Aubain N, Lemort M, Andry G (2011) Parathyroid
Carcinoma: A review with three illustrative cases. J Cancer 2:532–537

15. Teh B, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R (1996) Autosomal dominant primary hyperparathyroidism and jaw tumour syndrome associated with renal harmatomas and cystic kidney disease. J Clin Endocrinol Metab 81:4204–4211

16. Scott R, Stiller C, Walker L, Rahman N (2006) Syndromes and constitutional abnormalities associated with Wilms tumour. J Med Genet 43(9):705–715

17. Bradley K, Hobbs M, Buley ID, Carpten J, Cavaco B et al (2005) Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 257:18–26